person · Reporting owner

Klein Lawrence Otto

Disclosed activity across 5 companies

Tapewire entity: 18148
SEC CIK: 0001762583

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	CBO & COO	August 16, 2022	August 18, 2022
Dyne Therapeutics, Inc.DYN · Entity 3948	Director	July 05, 2022	July 06, 2022
Jade Biosciences, Inc.JBIO · Entity 4757	Director	June 09, 2026	June 11, 2026
Jasper Therapeutics, Inc.JSPR · Entity 7588	Director	June 07, 2023	June 08, 2023
Oruka Therapeutics, Inc.ORKA · Entity 3781	Director · Chief Executive Officer	October 01, 2026	October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date August 16, 2022 · Filed August 18, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	12,500	Reported balance After 2022-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-16 · Grant · Acquired 12,500 · Balance 12,500 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries.

Dyne Therapeutics, Inc.

Report date July 05, 2022 · Filed July 06, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30	Direct	7,222	Reported balance After 2022-07-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-07-05 · Grant · Acquired 7,222 · Balance 7,222 F1: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

Jade Biosciences, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08	Direct	34,843	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Jasper Therapeutics, Inc.

Report date June 07, 2023 · Filed June 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-07	Direct	47,000	Reported balance After 2023-06-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-07 · Grant · Acquired 47,000 · Balance 47,000

Oruka Therapeutics, Inc.

Report date October 01, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	923,128	Ending reported balance After 2026-10-01 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-10-01 · Exercise / conversion · Acquired 25,000 · Balance 948,128 Row 2 · 2026-10-01 · Sale · Disposed 16,246 · Balance 931,882 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Row 3 · 2026-10-01 · Sale · Disposed 8,554 · Balance 923,328 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive. Row 4 · 2026-10-01 · Sale · Disposed 200 · Balance 923,128 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.
Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14	Direct	1,528,513	Reported balance After 2026-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-10-01 · Exercise / conversion · Disposed 25,000 · Balance 1,528,513 F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.

F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 2, 2026 23:54 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	Exercise / conversionEmployee Warrant (right to buy) · Derivative	25,000	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0000907654-26-000104 · form4.xml · derivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,528,513 Underlying: Common Stock · 25,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document
October 01, 2026 Filed Oct 2, 2026 23:54 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	200	$84.78	$16,956.00	Disclosure SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 923,128 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive. Read SEC document
October 01, 2026 Filed Oct 2, 2026 23:54 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	8,554	$84.03	$718,754.98	Disclosure SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 923,328 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive. Read SEC document
October 01, 2026 Filed Oct 2, 2026 23:54 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	16,246	$83.40	$1,354,882.28	Disclosure SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 931,882 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
October 01, 2026 Filed Oct 2, 2026 23:54 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	Exercise / conversionCommon Stock	25,000	$7.80	$195,000.00	Disclosure SEC source: 0000907654-26-000104 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 948,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 15, 2026 Filed Sep 15, 2026 23:15 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	2,452	$95.71	$234,680.92	Disclosure SEC source: 0000907654-26-000096 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,128 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document
September 01, 2026 Filed Sep 1, 2026 22:35 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	Exercise / conversionEmployee Warrant (right to buy) · Derivative	75,000	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0000907654-26-000087 · form4.xml · derivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,553,513 Underlying: Common Stock · 75,000 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. Read SEC document
September 01, 2026 Filed Sep 1, 2026 22:35 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	4,800	$92.44	$443,691.36	Disclosure SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 925,580 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive. Read SEC document
September 01, 2026 Filed Sep 1, 2026 22:35 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	63,596	$91.90	$5,844,237.09	Disclosure SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 930,380 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive. Read SEC document
September 01, 2026 Filed Sep 1, 2026 22:35 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	6,604	$90.79	$599,556.03	Disclosure SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 993,976 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
September 01, 2026 Filed Sep 1, 2026 22:35 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	Exercise / conversionCommon Stock	75,000	$7.80	$585,000.00	Disclosure SEC source: 0000907654-26-000087 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2026 Filed Jun 15, 2026 22:52 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	1,729	$69.69	$120,494.01	Disclosure SEC source: 0000907654-26-000062 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925,580 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:41 UTC	Jade Biosciences, Inc. JBIO · Entity 4757	GrantStock Option (Right to Buy) · Derivative	34,843	$0.00 Strike: $15.22	$0.00	Disclosure SEC source: 0001193125-26-267735 · ownership.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,843 Underlying: Common Stock · 34,843 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document
March 16, 2026 Filed Mar 17, 2026 20:10 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	SaleCommon Stock	1,729	$41.30	$71,407.70	Disclosure SEC source: 0000907654-26-000033 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 927,309 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document
January 23, 2026 Filed Jan 23, 2026 22:38 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	GrantEmployee Stock Option (right to buy) · Derivative	306,700	$0.00 Strike: $34.39	$0.00	Disclosure SEC source: 0000907654-26-000015 · form4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,700 Underlying: Common Stock · 306,700 shares Expires 2036-01-22 F2 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document
January 23, 2026 Filed Jan 23, 2026 22:38 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	GrantCommon Stock	76,700	$0.00	$0.00	Disclosure SEC source: 0000907654-26-000015 · form4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 929,038 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). Read SEC document
April 29, 2025 Filed May 1, 2025 22:10 UTC	Jade Biosciences, Inc. JBIO · Entity 4757	GrantStock Option (Right to Buy) · Derivative	23,017	$0.00 Strike: $10.14	$0.00	Disclosure SEC source: 0000950170-25-062107 · ownership.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,017 Underlying: Common Stock · 23,017 shares Expires 2035-04-29 F1 · derivative.exercise_date: This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer. Read SEC document
January 22, 2025 Filed Jan 24, 2025 21:41 UTC	Oruka Therapeutics, Inc. ORKA · Entity 3781	GrantEmployee Stock Option (right to buy) · Derivative	230,000	$0.00 Strike: $12.50	$0.00	Disclosure SEC source: 0001062993-25-001085 · form4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. Read SEC document
June 07, 2023 Filed Jun 8, 2023 22:44 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	47,000	$0.00 Strike: $1.60	$0.00	Disclosure SEC source: 0001213900-23-047573 · ownership.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Voting Common Stock · 47,000 shares Expires 2033-06-07 Read SEC document
October 12, 2022 Filed Oct 14, 2022 00:07 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantVoting Common Stock	24,500	$0.00	$0.00	Disclosure SEC source: 0001213900-22-063947 · ownership.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 F1 · shares: The reported securities are represented by restricted stock units, 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document
August 16, 2022 Filed Aug 18, 2022 21:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantRestricted Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001209191-22-046709 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries. F2 · derivative.expiration_date: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries. Read SEC document
July 05, 2022 Filed Jul 6, 2022 22:20 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	7,222	$0.00 Strike: $5.54	$0.00	Disclosure SEC source: 0001209191-22-041335 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,222 Underlying: Common Stock · 7,222 shares Expires 2030-07-30 F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document
June 03, 2022 Filed Jun 6, 2022 20:07 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	19,596	$0.00 Strike: $4.58	$0.00	Disclosure SEC source: 0001209191-22-034493 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,596 Underlying: Common Stock · 19,596 shares Expires 2032-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document
March 21, 2022 Filed Mar 23, 2022 22:05 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	78,045	$0.00 Strike: $3.54	$0.00	Disclosure SEC source: 0001213900-22-014570 · ownership.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,045 Underlying: Voting Common Stock · 78,045 shares Expires 2032-03-21 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option shall vest on December 7, 2022, and 1/3rd of the shares subject to the option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document
March 14, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Tax withholdingCommon Shares	1,229	$61.08	$75,067.32	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,797 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionRestricted Stock Units · Derivative	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · derivative · entry 6 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F4 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025. F4 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document
March 11, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Tax withholdingCommon Shares	1,883	$62.56	$117,800.48	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document
March 10, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionRestricted Stock Units · Derivative	4,584	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · derivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Underlying: Common Shares · 4,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document
March 10, 2022 Filed Mar 14, 2022 22:03 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	4,584	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-018611 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document
February 18, 2022 Filed Feb 22, 2022 22:41 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantRestricted Stock Units · Derivative	20,400	$0.00	$0.00	Disclosure SEC source: 0001209191-22-011838 · doc4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Shares · 20,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 20,400 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 20,400 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document
February 18, 2022 Filed Feb 22, 2022 22:41 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	46,200	$0.00 Strike: $58.29	$0.00	Disclosure SEC source: 0001209191-22-011838 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,200 Underlying: Common Shares · 46,200 shares Expires 2032-02-18 F1 · derivative.exercise_date: This option was granted on February 18, 2022 with respect to 46,200 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022. Read SEC document
December 06, 2021 Filed Dec 8, 2021 01:00 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Tax withholdingCommon Shares	11,185	$69.17	$773,666.45	Disclosure SEC source: 0001209191-21-068455 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,325 F3 · kind: On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document
December 03, 2021 Filed Dec 8, 2021 01:00 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionRestricted Stock Units · Derivative	26,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-068455 · doc4.xml · derivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Shares · 26,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document
December 03, 2021 Filed Dec 8, 2021 01:00 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	26,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-068455 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document
October 15, 2021 Filed Oct 19, 2021 00:00 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,800	$0.00 Strike: $97.00	$0.00	Disclosure SEC source: 0001209191-21-060776 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Shares · 13,800 shares Expires 2031-10-15 F1 · derivative.exercise_date: This option was granted on October 15, 2021 with respect to 13,800 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 15, 2021. Read SEC document
September 13, 2021 Filed Sep 15, 2021 01:44 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Tax withholdingCommon Shares	4,207	$117.86	$495,837.02	Disclosure SEC source: 0001209191-21-056092 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,843 F3 · kind: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document
September 10, 2021 Filed Sep 15, 2021 01:44 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Tax withholdingRestricted Stock Units · Derivative	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-056092 · doc4.xml · derivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. F1 · derivative.expiration_date: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. Read SEC document
September 10, 2021 Filed Sep 15, 2021 01:44 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-056092 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document
May 26, 2021 Filed May 28, 2021 00:38 UTC	Dyne Therapeutics, Inc. DYN · Entity 3948	GrantStock Option (right to buy) · Derivative	19,596	$0.00 Strike: $19.56	$0.00	Disclosure SEC source: 0000899243-21-020989 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,596 Underlying: Common Stock · 19,596 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $44.67	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 14 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Shares · 12,000 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $40.87	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 13 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 20,000 shares Expires 2029-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $29.87	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 12 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $51.49	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 11 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Shares · 22,000 shares Expires 2028-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the seventh day of each month, with the first vesting event on April 7, 2018. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $17.66	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 10 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Shares · 12,000 shares Expires 2027-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on December 15, 2017. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $14.43	$0.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · derivative · entry 9 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Shares · 12,000 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	12,000	$126.97	$1,523,640.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 8 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $130.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	88,000	$128.20	$11,281,600.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 7 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.78 to $132.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	12,000	$17.66	$211,920.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 6 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 23, 2021 Filed Mar 25, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	Exercise / conversionCommon Shares	12,000	$14.43	$173,160.00	Disclosure SEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.